Abstract: A method to aid in the diagnosis of Alzheimer's disease in a living patient is disclosed which tests cerebrospinal fluid (CSF) obtained from the patient. The CSF is tested using a Western blot analysis to determine the presence of an antigen present in soluble paired helical filaments which specifically binds to the monoclonal antibody produced by hybridoma ATCC HD11079.

Abstract: An assay is provided in which a target ligand is detected in a biological specimen. The method involves treating the target ligand with detergent and then binding the treated ligand to a particle by means of a capturing substance on the particle, thereby forming a complex. The complex is then applied to a porous membrane having a charge similar to that of a glass fiber filter in order to immobilize the complex in the porous membrane. The pore size of the membrane is substantially larger than the size of the complex such that the immobilization of the complex is substantially accomplished by means of the attraction of the complex to the charge of the porous membrane, and not as a function of the pore size of the membrane. Thereafter, the presence of the complex in the porous membrane is detected.

Abstract: The invention is a method for detecting pathogenic bacteria by specific binding of the bacteria to GalNAc.beta.1-4Gal sequences found in fucosyl-asialo GM1, asialo GM1 and asialo GM2. An agglutination reaction is disclosed comprising contacting a culture suspected of containing the bacteria with a suspension of a purified carbohydrate compound bound to an insoluble carrier and detecting the presence of perceptible agglutination of the carrier as an indication of the presence of the bacteria. Bacteria which can be detected using the claimed method include Pseudomonas, Haemophilus, Staphylococcus, Klebsiella and Streptococcus pneumoniae.

Abstract: The present disclosure is directed to a peptide having active binding sites in a protein wherein the binding sites attract and hold antibodies for schistosomiasis in humans. A test reagent is set forth. Separate binding sites in the complex protein have been identified, and the binding sites in such reagent define the mechanism whereby the antibodies in the human serum provide a test reaction.

Abstract: Induction of virulence related proteins in virulent pathogenic E. coli and Shigella by growing such bacteria in the presence of Congo Red as induction triggering factor, and the application of the induction for purposes of diagnosing virulent pathogens and their antibiotic sensitivity.

Abstract: The subject invention relates to methods and kits for detecting or evaluating risk of presently or later developing active periodontitis, comprising: (a) collecting gingival crevicular fluid; (b) measuring the amount in the gingival crevicular fluid of IgA; (c) measuring the amount in the gingival crevicular fluid of a marker for polymorphonuclear leukocytes; (d) comparing a ratio of the amounts obtained from steps (b) and (c) to a standard.

Abstract: An ELISA method with competitive inhibition is described for determining antisporozoite antibodies of P. Falciparum in human blood samples and in mosquito extract, which uses a single plate pretreated with only the synthetic antigen (NANP).sub.20 using, as total competitive inhibitor for the formation of the complex between the synthetic antigen adsorbed on the plate and the antibody contained in the sample, the (NANP).sub.20 synthetic peptide in a weight ratio of at least 20:1 with respect to the adsorbed antigen. Because of its high specificity, sensitivity and speed, the method is particularly suitable for epidemiological studies on malaria.

Abstract: A buffered aqueous composition is useful simultaneously as a wash solution and a dye-providing composition in specific binding assays involving enzyme-labeled specific binding reagents. The wash composition includes a dye-providing composition, a buffer and an organic solvent having a certain molecular weight and water-solubility. Another useful composition includes a particulate substrate having avidin attached thereto, and a peroxidase reducing agent. Either composition can be provided in a diagnostic test kit, and can be used to detect a specific binding ligand in assays.

Abstract: The present invention provides recombinant DNA molecules comprising a sequence encoding a pseudorabies virus (PRV) glycoprotein selected from the group consisting of gI, gp50, and gp63, host cells transformed by said recombinant DNA molecule sequences, the gI, gp50 and gp63 polypeptides. The present invention also provides subunit vaccines for PRV, methods for protecting animals against PRV infection and methods for distinguishing between infected and vaccinated animals.

Abstract: A method of testing for tuberculosis and leprosy in animals or humans and antigens used in the method. The method involves carrying out an assay on sera from humans or animals using an antigen to bind antibodies in sera. The antigens used in the method are synthetic pseudo cord factor-like glycolipids having the structures (I) or (II) below: ##STR1## wherein R represents a straight or branched chain alkyl group having 15 to 18 carbon atoms. The antigens can be produced by chemical synthesis, and can therefore be made available in suitable quantities, and are relatively stable at ambient temperatures while showing good sensitivity and specificity for tuberculosis and leprosy. The antigens can be used, for example, for enzyme-linked immunosorbent assays, and related "spot tests" for diagnosing tuberculosis and leprosy.

Abstract: Assays which aid in diagnosing systemic lupus erythematosus and rheumatoid arthritis are disclosed. One assay tests urine samples for the presence or absence of an RNA polymerase I antibody which specifically binds with RNA polymerase I antigen and another assay tests for the presence or absence of an RNA polymerase I antigen that specifically binds with an antibody to RNA polymerase I.

Abstract: A stable antigen useful in the detection of Fasciola hepatica (or liver fluke) infections is disclosed. The antigen may be found in feces, bile, and intestinal contents. Monoclonal antibodies useful in detecting the antigen are disclosed. The method of this invention facilitates the detection of current Fasciola hepatica infections.

Abstract: An extraction composition is described which is buffered to a pH from about 8 to about 11 and which contains from about 1 to about 10 weight percent of a water-soluble cationic surfactant which is a quaternary ammonium salt or a mixture thereof and from about 1 to about 10 weight percent of an anionic surfactant which has a sulfate anion having from 6 to 14 carbon atoms and an alkali metal or ammonium cation. The extraction composition is used to extract antigens from Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis or Prevotella intermedia. Extracted antigens are determined using immunological methods. The extraction composition can be supplied as part of a diagnostic test kit.

Abstract: The invention relates to a method of preparing a reagent for the determination by hemagglutination of antibodies to bacterial toxins. According to this method erythrocytes are treated with glutaraldehyde and then with the bacterial toxins in the presence of glutaraldehyde without a wash step. The reagent thus obtained is further treated with a reagent for blocking aldehyde groups.

Abstract: A method for detecting a glycoprotein using a solid support is disclosed where the glycoprotein is oxidized by periodate, polyacrylic polyhydrazide which is a copolymer having repeating units possessing a hydrazide group and repeating units possessing hydroxyl groups is coupled to the oxidized glycoprotein and a glycoenzyme or radioactive compound containing aldehyde groups or activated ketone groups is coupled to the polyacrylic polyhydrazide which allows for detection of the glycoprotein. The glycoprotein may be directly attached to the solid support or may be bound to an antigen which is immobilized on the solid support.

Abstract: Methods for purifying and detecting IgM antibodies employ binding substances which are Borellia burgdorferi cells, or cellular or extracellular components obtained or derived therefrom and which bind to this class of antibodies. The binding substances may be attached to a solid substrate and then the substrate contacted with a solution containing IgM antibodies under conditions such that the antibodies bind to the binding substance on the substrate. The substrate is then contacted with a solution that releases the IgM antibodies from the substrate and the antibodies are recovered or detected. Applications of these methods include, for example, assays for diagnosing diseases which elicit primary and/or secondary IgM antibody-mediated immunity.

Abstract: Mouse monoclonal antibodies which will specifically recognize the pathogen Listeria monocytogenes were produced by fusion of spleen cells from an animal immunized with live L. monocytogenes to an NS-1 myeloma partner, and three hybridomas were identified upon subsequent subcloning, Mab 20-10-2, Mab 36-6-12 and Mab 56-9-16 which were preferentially reactive with L. monocytogenes in a direct binding ELISA assay. An indirect "sandwich" assay was developed and used to further confirm the reactivity of these hybridomas using four serotypes of L. monocytogenes and other common cross reacting bacteria.

Abstract: A monoclonal antibody which binds preferentially to colonic glycoproteins of cells of persons having ulcerative colitis, compared to colonic glycoproteins of cells of persons not having ulcerative colitis, and diagnostic and therapeutic uses thereof.

Abstract: In order to aid in the detection of malignant diseases the sample of a body fluid is incubated with at least two receptors R.sub.1 and R.sub.2 in which a signal change is produced by binding of at least the receptors R.sub.1 and R.sub.2 to the substance to be detected in the sample solution and in which one of the two receptors contains a monoclonal antibody which binds to the amino acid sequence 311 to 335 of cytokeratin 19 and the other receptor contains a monoclonal antibody which binds to the amino acid sequence 346 to 359 of cytokeratin 19 and the signal change in the sample caused by the binding is determined.

Abstract: The type of a blood specimen is determined by adding a portion thereof, either a diluted solution of its red cells or a portion of its plasma, to each of a multiplicity of wells in a transparent tray, by adding a blood type specific reagent to each of the wells in the tray, different reagents being added to different ones of the wells of the tray, periodically tilting the tray at a substantial angle of at least approximately 50.degree.